Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 96

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 96
---
 on the actual public offering price and other
terms of this offering determined at pricing.

You should read this table
in conjunction with the sections titled “Use of Proceeds”, “Selected Financial Data”, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes included
elsewhere in this prospectus.

|                                 |     | As of December 31, 2024 |         |   |     |           |        |   |     |                |       |
|:--------------------------------|:----|:------------------------|--------:|:--|:----|:----------|-------:|:--|:----|:---------------|------:|
| U.S. dollars in thousands       |     | Actual                  |         |   |     | Pro Forma |        |   |     | Pro            
 Forma          
 As Adjusted(1) |       |
| Cash and cash equivalents       |     |                         |     229 |   |     |           |    529 |   |     |                | 7,862 |
| Short term loan                 |     |                         |     573 |   |     |           |    873 |   |     |                |     - |
| Convertible note                |     |                         |   4,372 |   |     |           |      - |   |     |                |     - |
| Warrant liability               |     |                         |     160 |   |     |           |      - |   |     |                |     - |
| Other current liabilities       |     |                         |   1,383 |   |     |           |  1,383 |   |     |                | 1,203 |
|                                 |     |                         |   6,488 |   |     |           |  2,256 |   |     |                | 1,203 |
| Long term liabilities           |     |                         |       - |   |     |           |      - |   |     |                |     - |
| Total Temporary equity          |     |                         |  35,098 |   |     |           |      - |   |     |                |     - |
| Shareholders’ equity (deficit): |     |                         | (41,104 | ) |     |           | (1,474 | ) |     |                | 6,732 |
| Total capitalization            |     |                         |